to develop an anti-SARS-CoV-2 mAb product for prevention of severe COVID-19 in vulnerable populations in low and middle income countries

Grant number: INV-024617

Grant search

Key facts

  • Disease

    COVID-19
  • start year

    2020
  • Known Financial Commitments (USD)

    $223,307
  • Funder

    Gates Foundation
  • Principal Investigator

    N/A

  • Research Location

    Netherlands
  • Lead Research Institution

    Academisch Medisch Centrum
  • Research Priority Alignment

    N/A
  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Vulnerable populations unspecified

  • Occupations of Interest

    Unspecified

Abstract

N/A

Publicationslinked via Europe PMC

Last Updated:42 minutes ago

View all publications at Europe PMC

Plant-produced SARS-CoV-2 antibody engineered towards enhanced potency and in vivo efficacy.

A public antibody class recognizes an S2 epitope exposed on open conformations of SARS-CoV-2 spike.

Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study.

A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike.

Cross-reactive antibodies after SARS-CoV-2 infection and vaccination.

Probing Affinity, Avidity, Anticooperativity, and Competition in Antibody and Receptor Binding to the SARS-CoV-2 Spike by Single Particle Mass Analyses.

Saliva SARS-CoV-2 Antibody Prevalence in Children.